alexa Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
Orthopaedics

Orthopaedics

Journal of Arthritis

Author(s): Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM,

Abstract Share this page

Abstract BACKGROUND: In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in rheumatoid arthritis over 3 months. OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in patients with rheumatoid arthritis. DESIGN: Randomized, double-blind, placebo-controlled trial with blinded joint assessors. SETTING: 13 North American centers. PATIENTS: 234 patients with active rheumatoid arthritis who had an inadequate response to disease-modifying antirheumatic drugs. INTERVENTION: Twice-weekly subcutaneous injections of etanercept, 10 or 25 mg, or placebo for 6 months. MEASUREMENTS: The primary end points were 20\% and 50\% improvement in disease activity according to American College of Rheumatology (ACR) responses at 3 and 6 months. Other end points were 70\% ACR responses at 3 and 6 months and other measures of disease activity at 3 and 6 months. RESULTS: Etanercept significantly reduced disease activity in a dose-related fashion. At 3 months, 62\% of the patients receiving 25 mg of etanercept and 23\% of the placebo recipients achieved 20\% ACR response (P < 0.001). At 6 months, 59\% of the 25-mg group and 11\% of the placebo group achieved a 20\% ACR response (P < 0.001); 40\% and 5\%, respectively, achieved a 50\% ACR response (P < 0.01). The respective mean percentage reduction in the number of tender and swollen joints at 6 months was 56\% and 47\% in the 25-mg group and 6\% and -7\% in the placebo group (P < 0.05). Significantly more etanercept recipients achieved a 70\% ACR response, minimal disease status (0 to 5 affected joints), and improved quality of life. Etanercept was well tolerated, with no dose-limiting toxic effects. CONCLUSIONS: Etanercept can safely provide rapid, significant, and sustained benefit in patients with active rheumatoid arthritis.
This article was published in Ann Intern Med and referenced in Journal of Arthritis

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords